With earnings growing while its stock price has fallen, VICI has gotten a lot cheaper over the past year. In its S-1, Kenvue notes that the consumer health market grew at a compound annual growth rate (CAGR) of 4.8% from 2019 to 2022, and management believes the market will continue to grow at a CAGR of 3 to 4% globally through 2025. As a provider of some of the largest consumer health products in the world, Kenvue generated nearly $15 billion in revenue in 2022 and $2.3 billion in net operating profit find programmers for startup after tax (NOPAT). In 2022, NOPAT was up 8% year-over-year (YoY) while revenue was down 1%, per Figure 1. Dr. Tabibiazar is a seasoned executive with leadership experience in the healthcare and biopharma industries, including venture capital, pharmaceuticals and diagnostics. As a clinician-entrepreneur and managing director of ” 526 Ventures “, he has focused on creating new ventures in the form of new companies or spinouts to translate innovative science into commercially viable products.
- This scenario implies Kenvue grows NOPAT by 7% compounded annually through 2029.
- AT&T signaled months ahead of time that it would spin off WarnerMedia and cut its dividend accordingly.
- That likely rules it out as a good purchase for value-sensitive investors, and of course, there’s little reason for growth-seeking investors to approach it either.
- Medical startups in North America tend to receive significantly higher valuations than they would in other markets.
Kenvue is producing healthy cash flow, which allowed it to initiate a dividend and launch a share repurchase program. The company’s growing sales, profits, and cash flow should enable it to follow in the footsteps of its former parent and steadily increase its dividend in the future. That growth should help drive the stock price higher https://traderoom.info/ over the future, which should enable Kenvue to deliver healthy total returns. Analyst Rohit Kulkarni of Roth MKM has also touted the new stock’s potential, noting that Kenvue’s sector benefits from inflation-driven tailwinds. The larger firm plans to distribute the remaining 1.7 billion shares later, likely in the second half of 2023.
“Thanks to the strong contributions from our team, we delivered differentiated performance in 2023 and enabled our customers’ success,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “We effectively navigated the challenging macroeconomic conditions by leveraging our PPI Business System to deliver strong financial results.” Although standards in the EU are generally more stringent, that doesn’t necessarily mean adherence to North American regulations such as the US Food and Drug Administration is easy. Regulatory compliance is often incredibly complex and in many cases a medical startup might not have the resources to manage it in multiple regions. It also helps that the Nordic countries consistently rank among the happiest places in the world.
In addition to healthcare, the Swiss government invests heavily in research and development across multiple sectors. As a result, even though its population totals just over 8.7 million, Switzerland holds the world’s third-highest number of patents per capita, just behind the United States and Japan. The Consumer Health segment generated revenue of $14.6 billion in Full-Year 2021 and, following the planned separation, Kenvue would generate sales in over 100 countries, driven by world-class innovation capabilities and demonstrated business momentum. “We believe that daily self-care rituals add up over time and have a profound cumulative impact on your wellbeing. This is the extraordinary power of everyday care. And our work is to put that power into the hands of consumers around the world,” Mongon adds. The spinoff, the biggest IPO since EV maker Rivian went public in November 2021, alone may not completely turn around the moribund IPO market, which plummeted in 2022. We’ve always believed in the power of new perspectives and insights to drive innovation.
What is Kenvue? 8 important things to know about us
Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. Kenvue is a compact yet powerful name that stands for the fusion of knowledge and vision. “Ken” is an English word meaning “to know,” and “vue” is French, referring to insight.
This in turn enables faster, more accurate treatment of stroke patients, exponentially improving patient outcomes in the process. Headquartered in Barcelona, Spain, the startup’s multidisciplinary leadership includes medical experts, key opinion leaders and veteran healthcare entrepreneurs. Bringing European healthcare technologies to the North American market can potentially improve healthcare in this part of the world, open up new market opportunities for investors and expose those companies to significant growth capital. Along with the name and purpose, Kenvue’s visual identity represents the company’s timelessness, while allowing space for its iconic brands to also have a home.
That’s not necessarily a negative, as it will mean plenty of incentive for the company to be run prudently because Johnson & Johnson will still have a lot of skin in the game. That means less risk-taking and perhaps more conservatism, which caters to the preferences of dividend investors rather than to those looking for an aggressive growth stock. Although Kenvue is technically a separate company, Johnson & Johnson will still play a big role in its operations; the healthcare company will own a 90% stake in the business. From a patient’s first visit to the doctor to ongoing care at home – our products deliver safe, effective, everyday care at every stage of life. Dividend Aristocrats are an elite group of dividend-paying stocks that offer low volatility, a dual return profile and reliable, inflation-friendly income. To defer all taxes on dividend income, hold these investments in a tax-advantaged account such as an IRA.
Innovations and Opportunities in European Healthcare Technologies
On the date of publication, Samuel O’Brient did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. Our proprietary measures of Core Earnings and Earnings Distortion materially improve stock picking and forecasting of profits.
Top 8 Canadian Lithium Stocks
J&J will generally be able to control matters that shareholders vote on, such as the election of directors to Kenvue’s board, the filing said. J&J will control 91.9% of Kenvue after the IPO — or 90.8% if underwriters exercise their options to purchase additional shares, according to the prospectus filing. Meanwhile, Kenvue is chock full of household names familiar to investors and the larger public, such as Tylenol, Band-Aid, Listerine, Aveeno, Neutrogena, and J&J’s namesake baby powder and shampoo. Kenvue’s debut also marks the largest restructuring in J&J’s 135-year history.
Are Dividend Aristocrats Safe Investments?
In this scenario, Kenvue’s revenue would still grow to $19.7 billion in 2029, or 4% compounded annually. This scenario also implies the company would earn $3.1 billion in NOPAT and grow NOPAT 4% compounded annually through 2029. For reference, Kenvue’s NOPAT has fallen 5% compounded annually since 2020. In other words, even if Kenvue improves margins and grows revenue at the high end of management’s estimate, the stock is worth only $18/share. For reference, Kenvue’s economic book value, or no growth value, is $14/share. At FN Media Group, via our top-rated online news portal at , we are one of the very few select firms providing top tier one syndicated news distribution, targeted ticker tag press releases and stock market news coverage for today’s emerging companies.
Organic revenue was 5% lower, Core organic revenue growth was 1%, and COVID-19 testing revenue was $0.33 billion. The company must have some unique selling point or value proposition that clearly differentiates it from others in its field. With that in mind, a portfolio of disruptive technologies with very clear applications for patients and physicians is also a must. German-Irish medtech company LUMA Vision — formerly OneProjects — is developing a new technology platform that it believes will revolutionize the treatment of cardiac arrhythmias and atrial fibrillation. Known as VERAFEYE, the technology will leverage data analytics and advanced imaging to provide physicians with a four dimensional view of the heart. The startup raised $17 million to support the development of its technology in 2021.